State Board of Administration of Florida Retirement System Sells 7,250 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD)

State Board of Administration of Florida Retirement System reduced its stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 32.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 15,100 shares of the company’s stock after selling 7,250 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Relmada Therapeutics were worth $53,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. RTW Investments LP increased its stake in shares of Relmada Therapeutics by 0.3% during the third quarter. RTW Investments LP now owns 2,644,475 shares of the company’s stock valued at $97,898,000 after purchasing an additional 6,894 shares in the last quarter. Perceptive Advisors LLC grew its holdings in shares of Relmada Therapeutics by 1,864.1% during the third quarter. Perceptive Advisors LLC now owns 2,383,478 shares of the company’s stock valued at $88,236,000 after buying an additional 2,262,128 shares during the last quarter. BVF Inc. IL grew its holdings in shares of Relmada Therapeutics by 25.3% during the third quarter. BVF Inc. IL now owns 2,078,220 shares of the company’s stock valued at $76,936,000 after buying an additional 419,000 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Relmada Therapeutics by 41.0% during the first quarter. BlackRock Inc. now owns 1,952,808 shares of the company’s stock valued at $52,707,000 after buying an additional 567,573 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Relmada Therapeutics by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,443,960 shares of the company’s stock valued at $53,456,000 after buying an additional 20,928 shares during the last quarter. 97.76% of the stock is owned by institutional investors.

Relmada Therapeutics Stock Down 5.7 %

NASDAQ:RLMD opened at $3.13 on Wednesday. The company’s 50 day moving average price is $2.69 and its 200-day moving average price is $3.55. Relmada Therapeutics, Inc. has a 52 week low of $1.81 and a 52 week high of $38.68. The stock has a market cap of $94.21 million, a price-to-earnings ratio of -0.66 and a beta of 0.16.

Relmada Therapeutics (NASDAQ:RLMD – Get Rating) last issued its earnings results on Thursday, March 23rd. The company reported ($1.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.07. As a group, sell-side analysts anticipate that Relmada Therapeutics, Inc. will post -3.71 earnings per share for the current year.

Relmada Therapeutics Profile

(Get Rating)

Relmada Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications.